Zealand Pharma A/S (ZLDPF)

43.00 0.00 (0.00%) USD  |  OTCM  |  Sep 18, 16:00
More

Zealand Pharma Total Long Term Debt (Quarterly) : 62.86M for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for ZLDPF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 62.86M
March 31, 2026 63.84M
December 31, 2025 63.80M
September 30, 2025 63.98M
June 30, 2025 62.46M
March 31, 2025 57.14M
December 31, 2024 54.40M
September 30, 2024 58.31M
June 30, 2024 56.05M
March 31, 2024 56.35M
December 31, 2023 17.67M
September 30, 2023 16.48M
June 30, 2023 17.12M
March 31, 2023 74.75M
December 31, 2022 75.21M
September 30, 2022 65.31M
June 30, 2022 68.24M
March 31, 2022 118.20M
December 31, 2021 120.40M
September 30, 2021 22.14M
June 30, 2021 22.93M
March 31, 2021 20.34M
December 31, 2020 21.39M
September 30, 2020 21.03M
June 30, 2020 20.63M
Date Value
March 31, 2020 14.88M
December 31, 2019 12.88M
September 30, 2019 10.00M
June 30, 2019 0.509M
March 31, 2019 0.8946M
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 22.48M
March 31, 2018 22.13M
December 31, 2017 21.89M
September 30, 2017 22.54M
June 30, 2017 21.84M
March 31, 2017 23.23M
December 31, 2016 46.65M
September 30, 2016 47.11M
June 30, 2016 46.47M
March 31, 2016 50.82M
December 31, 2015 45.55M
September 30, 2015 49.11M
June 30, 2015 44.23M
March 31, 2015 43.66M
December 31, 2014 44.23M
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Genmab A/S 4.979B
Ascendis Pharma A/S 439.76M
Bavarian Nordic A/S 19.76M
Evaxion AS 7.105M
ACADIA Pharmaceuticals, Inc. 59.55M